Spire Wealth Management’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.18K | Sell |
4
-1,105
| -100% | -$211K | ﹤0.01% | 2107 |
|
|
2026
Q1 | $184K | Sell |
1,109
-2
| -0.2% | -$328 | 0.01% | 803 |
|
|
2025
Q4 | $177K | Buy |
1,111
+3
| +0.3% | +$412 | 0.01% | 827 |
|
|
2025
Q3 | $104K | Buy |
1,108
+2
| +0.2% | +$141 | ﹤0.01% | 975 |
|
|
2025
Q2 | $63K | Buy |
1,106
+350
| +46% | +$18.6K | ﹤0.01% | 1122 |
|
|
2025
Q1 | $46.1K | Buy |
756
+4
| +0.5% | +$341 | ﹤0.01% | 1313 |
|
|
2024
Q4 | $67.7K | Buy |
+752
| New | +$88.5K | ﹤0.01% | 1169 |
|
|
2023
Q4 | – | Sell |
-716
| Closed | -$54.5K | – | 2422 |
|
|
2023
Q3 | $54.5K | Buy |
716
+116
| +19% | +$11.9K | ﹤0.01% | 1153 |
|
|
2023
Q2 | $71.1K | Hold |
600
| – | – | ﹤0.01% | 1075 |
|
|
2023
Q1 | $58.9K | Buy |
600
+100
| +20% | +$13.6K | ﹤0.01% | 1134 |
|
|
2022
Q4 | $71K | Buy |
500
+200
| +67% | +$27.9K | ﹤0.01% | 859 |
|
|
2022
Q3 | $42K | Hold |
300
| – | – | ﹤0.01% | 1011 |
|
|
2022
Q2 | $40K | Buy |
300
+132
| +79% | +$22.5K | ﹤0.01% | 1381 |
|
|
2022
Q1 | $52K | Buy |
+168
| New | +$63.3K | ﹤0.01% | 1434 |
|
|
2021
Q4 | – | Sell |
-10
| Closed | -$11K | – | 2973 |
|
|
2021
Q3 | $11K | Hold |
10
| – | – | ﹤0.01% | 2067 |
|
|
2021
Q2 | $15K | Buy |
+10
| New | +$13.9K | ﹤0.01% | 1986 |
|
Other funds holding LABU
Spire Wealth Management's LABU Position: Q2 2026 in Review
Spire Wealth Management reduced its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 100% in Q2 2026, selling an estimated $211K and leaving 4 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #2107.
Spire Wealth Management first reported a position in LABU in Q2 2021 and has held it in 16 quarters since. The position peaked at $184K in Q1 2026. 2 funds tracked by Wall St. Rank hold LABU as of Q2 2026.
- Spire Wealth Management held 4 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $1.18K as of Q2 2026.
- Spire Wealth Management sold 1,105 Direxion Daily S&P Biotech Bull 3X ETF shares in Q2 2026, an estimated $211K.
- Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #2107 holding.
- Spire Wealth Management first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2021 and has held it in 16 quarters since.
- Spire Wealth Management's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $184K in Q1 2026.
- 2 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2026.
Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.